0000000000520154

AUTHOR

Pablo Maroto

showing 2 related works from this author

Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation.

2014

Background: The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties. Methods: For the adaptation into Spanish we used the forward and back-translation method, expert panels, and cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered before and 12 months after treatment. Reliability was estimated by Cronbach’s alpha.…

MalePsychometricsAparell urinariSurveys and QuestionnairesProspective cohort studyCàncermedia_commonLanguageCognitionGeneral MedicinePatient outcomeControl de qualitatNeoplasias de la Vejiga UrinariaEstudios de ValidaciónPsicometríaBufeta -- CàncerFemalePsicometriaClinical psychologyCross-Cultural ComparisonQuality of lifemedicine.medical_specialtyPsychometricsUrinary bladder neoplasms:Psychiatry and Psychology::Behavioral Disciplines and Activities::Psychological Tests::Psychometrics [Medical Subject Headings]:Publication Characteristics::Study Characteristics::Validation Studies [Medical Subject Headings]Cronbach's alpha:Disciplines and Occupations::Social Sciences::Quality of Life [Medical Subject Headings]medicine:Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Urinary Bladder Neoplasms [Medical Subject Headings]media_common.cataloged_instanceHumansEuropean UnionEuropean unionAgedNeoplasm StagingGynecologyAnalysis of VarianceBladder cancerbusiness.industryResearchPublic Health Environmental and Occupational HealthConstruct validityTranslatingmedicine.diseaseCross-cultural studiesUnited StatesValidation studiesPatient outcomesCalidad de VidabusinessHealth and quality of life outcomes
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct